Submitted by Anonymous (not verified) on 26 September 2023 - 11:29
Human medicines European public assessment report (EPAR): Ultomiris, ravulizumab, Hemoglobinuria, Paroxysmal, Date of authorisation: 02/07/2019, Revision: 13, Status: Authorised
Source: